Brief: Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)
16/03/2026 12:13
March 16 (Reuters) - Cogent Biosciences Inc COGT.O: COGENT BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) COGENT BIOSCIENCES: BEZUCLASTINIB PDUFA TARGET ACTION DATE SET FOR DEC 30, 2026 Source text: ID:nGNXbNX9Pd Further company coverage: COGT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's